Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Silence Therapeutics Plc - American Depository Share (NQ:SLN)

6.600 -0.010 (-0.15%)
Streaming Delayed Price Updated: 9:52 AM EST, Nov 4, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Silence Therapeutics Plc - American Depository Share

< Previous 1 2 3 Next >
Silence Therapeutics Completes Enrollment in SANRECO Phase 2 Study of Divesiran for Polycythemia Vera (PV)
From Silence Therapeutics plc
Via Business Wire
Silence Therapeutics to Participate in September Investor Conferences
From Silence Therapeutics plc
Via Business Wire
Silence Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights
From Silence Therapeutics plc
Via Business Wire
Silence Therapeutics Presents Additional Phase 1 Data Highlighting Promise of Divesiran as the Potential First-in-Class siRNA Treatment for Polycythemia Vera
From Silence Therapeutics plc
Via Business Wire
Silence Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights
From Silence Therapeutics plc
Via Business Wire
Silence Therapeutics Welcomes Tim McInerney to Board of Directors
From Silence Therapeutics plc
Via Business Wire
Silence Therapeutics to Webcast Presentation at the Leerink Partners Global Healthcare Conference
From Silence Therapeutics plc
Via Business Wire
Silence Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update
From Silence Therapeutics plc
Via Business Wire
Silence Therapeutics to Report Fourth Quarter and Full Year 2024 Results on February 27, 2025
From Silence Therapeutics plc
Via Business Wire
Silence Therapeutics Presents Promising Phase 1 Data in Polycythemia Vera Patients at the American Society of Hematology (ASH) Annual Meeting
From Silence Therapeutics plc
Via Business Wire
Silence Therapeutics to Participate in Fireside Chat at Piper Sandler 36th Annual Healthcare Conference
From Silence Therapeutics plc
Via Business Wire
Silence Therapeutics Presents Late-Breaking Phase 2 Zerlasiran Data at 2024 American Heart Association (AHA) Annual Meeting
From Silence Therapeutics plc
Via Business Wire
Silence Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
From Silence Therapeutics plc
Via Business Wire
Silence Therapeutics to Participate in Fireside Chat at the Jefferies London Healthcare Conference
From Silence Therapeutics plc
Via Business Wire
Silence Therapeutics to Webcast Presentations at Upcoming September Investor Conferences
From Silence Therapeutics plc
Via Business Wire
Silence Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
From Silence Therapeutics plc
Via Business Wire
Silence Therapeutics Announces Positive Results from Ongoing SANRECO Phase 1 Study of Divesiran in Polycythemia Vera Patients
From Silence Therapeutics plc
Via Business Wire
Silence Therapeutics Achieves $2 Million Research Milestone Payment from Hansoh Pharma Collaboration
From Silence Therapeutics plc
Via Business Wire
Silence Therapeutics Announces Positive Topline 48-Week Data from Phase 2 Study of Zerlasiran in Patients with Elevated Lipoprotein(a)
From Silence Therapeutics plc
Via Business Wire
Silence Therapeutics to Present at Jefferies Global Healthcare Conference
From Silence Therapeutics plc
Via Business Wire
Silence Therapeutics Reports First Quarter 2024 Results and Highlights Pipeline Progress
From Silence Therapeutics plc
Via Business Wire
Silence Therapeutics to Participate in Fireside Chat at H.C. Wainwright 2nd Annual BioConnect Investor Conference
From Silence Therapeutics plc
Via Business Wire
Silence Therapeutics Announces Retirement of Alistair Gray from Board of Directors
From Silence Therapeutics plc
Via Business Wire
Silence Therapeutics Announces JAMA Publication of Additional Phase 1 Data for Zerlasiran in Subjects with Elevated Lipoprotein(a)
From Silence Therapeutics plc
Via Business Wire
Silence Therapeutics Reports Full Year 2023 Financial Results and Recent Business Highlights
From Silence Therapeutics plc
Via Business Wire
Silence Therapeutics Announces Positive Topline 36-Week Data from Ongoing Phase 2 Study of Zerlasiran in Patients with High Lipoprotein(a)
From Silence Therapeutics plc
Via Business Wire
Silence Therapeutics to Report Fourth Quarter and Full Year 2023 Results on March 13, 2024
From Silence Therapeutics plc
Via Business Wire
Silence Therapeutics Achieves $10 Million Milestone Payment from AstraZeneca Collaboration Following the Initiation of Phase 1 Trial
From Silence Therapeutics plc
Via Business Wire
Silence Therapeutics Announces Oversubscribed $120 Million Private Placement
From Silence Therapeutics plc
Via Business Wire
Silence Therapeutics to Participate in Fireside Chat at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
From Silence Therapeutics plc
Via Business Wire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.